LawPlayer
My bookmarksSign up freeSign up free
Source

Commission Regulation (EU) 2016/1179 of 19 July 2016 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)

Commission Regulation (EU) 2016/1179 of 19 July 2016 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)

Regulation (EU) 2016/1179 · Regulation · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Regulation (EC) No 1272/2008 is amended as follows: (1) Annex VI is amended in accordance with the Annex to this Regulation; (2) in Annex VI, Table 3.2 is deleted.

Article 2

Open ↗

1.   This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . 2.   This Regulation shall apply from 1 March 2018. Article 1(2) shall apply from 1 June 2017. 3.   By way of derogation from paragraph 2, substances and mixtures may, before 1 March 2018, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows: (a) the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted; (b) the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively: Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘006-035-00-8 pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate 245-430-1 23103-98-2 Carc. 2 Acute Tox. 3 Acute Tox. 3 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H331 H301 H317 H400 H410 GHS08 GHS06 GHS09 Dgr H351 H331 H301 H317 H410   M = 10 M = 100’   ‘029-002-00-X dicopper oxide; copper (I) oxide 215-270-7 1317-39-1 Acute Tox. 4 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H318 H400 H410 GHS07 GHS05 GHS09 Dgr H332 H302 H318 H410   M = 100’   ‘602-020-00-0 1,2-dichloropropane; propylene dichloride 201-152-2 78-87-5 Flam. Liq. 2 Carc. 1B Acute Tox. 4* Acute Tox. 4* H225 H350 H332 H302 GHS02 GHS08 GHS07 Dgr H225 H350 H332 H302’       ‘602-033-00-1 chlorobenzene 203-628-5 108-90-7 Flam. Liq. 3 Acute Tox. 4 Skin Irrit. 2 Aquatic Chronic 2 H226 H332 H315 H411 GHS02 GHS07 GHS09 Wng H226 H332 H315 H411’       ‘603-055-00-4 propylene oxide; 1,2-epoxypropane; methyloxirane 200-879-2 75-56-9 Flam. Liq. 1 Carc. 1B Muta. 1B Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Irrit. 2 H224 H350 H340 H331 H311 H302 H335 H319 GHS02 GHS08 GHS06 Dgr H224 H350 H340 H331 H311 H302 H335 H319’       ‘604-030-00-0 bisphenol A; 4,4′-isopropylidenediphenol 201-245-8 80-05-7 Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 H360F H335 H318 H317 GHS08 GHS05 GHS07 Dgr H360F H335 H318 H317’       ‘604-092-00-9 phenol, dodecyl-, branched; [1] phenol, 2-dodecyl-, branched; [2] phenol, 3-dodecyl-, branched; [3] phenol, 4-dodecyl-, branched; [4] phenol, (tetrapropenyl) derivatives [5] 310-154-3 [1] [2] [3] [4] [5] 121158-58-5 [1] [2] [3] 210555-94-5 [4] 74499-35-7 [5] Repr. 1B Skin Corr. 1C Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H360F H314 H318 H400 H410 GHS08 GHS05 GHS09 Dgr H360F H314 H410   M = 10 M = 10’   ‘605-013-00-0 chloralose (INN); (R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral 240-016-7 15879-93-3 Acute Tox. 4* Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 H332 H301 H336 H400 H410 GHS06 GHS09 Dgr H332 H301 H336 H410   M = 10 M = 10 C’ ‘605-022-00-X glutaral; glutaraldehyde; 1,5-pentanedial 203-856-5 111-30-8 Acute Tox. 2 Acute Tox. 3 STOT SE 3 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 H330 H301 H335 H314 H334 H317 H400 H411 GHS06 GHS05 GHS08 GHS09 Dgr H330 H301 H335 H314 H334 H317 H410 EUH071 STOT SE 3; H335: 0,5 % ≤ C < 5 % M = 1’   ‘606-014-00-9 chlorophacinone (ISO); 2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione 223-003-0 3691-35-8 Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H330 H310 H300 H372 (blood) H400 H410 GHS08 GHS06 GHS09 Dgr H360D H330 H310 H300 H372 (blood) H410   Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,1 % STOT RE 2; H373 (blood): 0,01 % ≤ C < 0,1 % M = 1 M = 1’   ‘606-021-00-7 N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone 212-828-1 872-50-4 Repr. 1B STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 H360D*** H335 H315 H319 GHS08 GHS07 Dgr H360D*** H335 H315 H319   STOT SE 3; H335: C ≥ 10 %’   ‘607-056-00-0 warfarin (ISO); 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1] (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2] (R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3] 201-377-6 [1] 226-907-3 [2] 226-908-9 [3] 81-81-2 [1] 5543-57-7 [2] 5543-58-8 [3] Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 2 STOT RE 1 Aquatic Chronic 2 H360D H330 H310 H300 H372 (blood) H411 GHS08 GHS06 GHS09 Dgr H360D H330 H310 H300 H372 (blood) H411   Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,5 % STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’   ‘607-059-00-7 coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin 227-424-0 5836-29-3 Repr. 1B Acute Tox. 2 Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Chronic 1 H360D H330 H311 H300 H372 (blood) H410 GHS08 GHS06 GHS09 Dgr H360D H330 H311 H300 H372 (blood) H410   Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 1,0 % STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 % M = 10’   ‘607-157-00-X difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin 259-978-4 56073-07-5 Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H330 H310 H300 H372 (blood) H400 H410 GHS08 GHS06 GHS09 Dgr H360D H330 H310 H300 H372 (blood) H410   Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 10 M = 10’   ‘607-172-00-1 brodifacoum (ISO); 4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin 259-980-5 56073-10-0 Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H330 H310 H300 H372 (blood) H400 H410 GHS08 GHS06 GHS09 Dgr H360D H330 H310 H300 H372 (blood) H410   Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 10 M = 10’   ‘607-375-00-5 flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin 421-960-0 90035-08-8 Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H330 H310 H300 H372 (blood) H400 H410 GHS08 GHS06 GHS09 Dgr H360D H330 H310 H300 H372 (blood) H410   Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,05 % STOT RE 2; H373 (blood): 0,005 % ≤ C < 0,05 % M = 10 M = 10’   ‘607-623-00-2 diisobutyl phthalate 201-553-2 84-69-5 Repr. 1B H360Df GHS08 Dgr H360Df’       ‘613-166-00-X flumioxazin (ISO); 2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione — 103361-09-7 Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 H360D H400 H410 GHS08 GHS09 Dgr H360D H410   M = 1 000 M = 1 000 ’   ‘613-121-00-4 chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide 265-268-5 64902-72-3 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 1 000 M = 100’   ‘616-011-00-4 N,N-dimethylacetamide 204-826-4 127-19-5 Repr. 1B Acute Tox. 4* Acute Tox. 4* H360D*** H332 H312 GHS08 GHS07 Dgr H360D*** H332 H312’       ‘616-037-00-6 acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide 251-899-3 34256-82-1 Carc. 2 Repr. 2 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H361f H332 H335 H373 (kidney) H315 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361f H332 H335 H373 (kidney) H315 H317 H410   M = 1 000 M = 100’   ‘616-207-00-X polyhexamethylene biguanide hydrochloride; PHMB — 32289-58-0 27083-27-8 Carc. 2 Acute Tox. 2 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H351 H330 H302 H372 (respiratory tract) (inhalation) H318 H317 H400 H410 GHS08 GHS06 GHS05 GHS09 Dgr H351 H330 H302 H372 (respiratory tract) (inhalation) H318 H317 H410   M = 10 M = 10’   (c) the following entries are inserted in accordance with the order of the index numbers: Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘005-020-00-3 disodium octaborate anhydrous; [1] disodium octaborate tetrahydrate [2] 234-541-0 [1] 234-541-0 [2] 12008-41-2 [1] 12280-03-4 [2] Repr. 1B H360FD GHS08 Dgr H360FD’       ‘014-046-00-4 e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO 2  50,0-56,0 %, Al 2 O 3  13,0-16,0 %, B 2 O 3  5,8-10,0 %, Na 2 O < 0,6 %, K 2 O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe 2 O 3 < 0,5 %, F 2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 1B H350i GHS08 Dgr H350i     A’ ‘014-047-00-X glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO 2  55,0-60,0 %, Al 2 O 3  4,0-7,0 %, B 2 O 3  8,0-11,0 %, ZrO 2  0,0-4,0 %, Na 2 O 9,5-13,5 %, K 2 O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe 2 O 3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F 2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 2 H351 (inhalation) GHS08 Wng H351 (inhalation)     A’ ‘029-015-00-0 copper thiocyanate 214-183-1 1111-67-7 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 EUH032 M = 10’   ‘029-016-00-6 copper(II) oxide 215-269-1 1317-38-0 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 100’   ‘029-017-00-1 dicopper chloride trihydroxide 215-572-9 1332-65-6 Acute Tox. 4 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H332 H301 H400 H410 GHS06 GHS09 Dgr H332 H301 H410   M = 10’   ‘029-018-00-7 tetracopper hexahydroxide sulphate; [1] tetracopper hexahydroxide sulphate hydrate [2] 215-582-3 [1] 215-582-3 [2] 1333-22-8 [1] 12527-76-3 [2] Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410   M = 10’   ‘029-019-01-X copper flakes (coated with aliphatic acid) — — Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 H302 H319 H400 H410 GHS06 GHS09 Dgr H331 H302 H319 H410   M = 10’   ‘029-020-00-8 copper(II) carbonate--copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H332 H302 H319 H400 H410 GHS07 GHS09 Wng H332 H302 H319 H410   M = 10’   ‘029-021-00-3 copper dihydroxide; copper(II) hydroxide 243-815-9 20427-59-2 Acute Tox. 2 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H318 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H302 H318 H410   M = 10’   ‘029-022-00-9 bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide — 8011-63-0 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H332 H318 H400 H410 GHS07 GHS05 GHS09 Dgr H332 H318 H410   M = 10’   ‘029-023-00-4 copper sulphate pentahydrate 231-847-6 7758-99-8 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H318 H400 H410 GHS07 GHS05 GHS09 Dgr H302 H318 H410   M = 10’   ‘082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. H360FD H362 GHS08 Dgr H360FD H362   Repr. 1A; H360D: C ≥ 0,03 %’   ‘082-014-00-7 lead massive: [particle diameter ≥ 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. H360FD H362 GHS08 Dgr H360FD H362’       ‘605-040-00-8 hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1] 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2] 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3] - [1] 250-863-4 [2] 257-187-9 [3] 130066-44-3 [1] 31906-04-4 [2] 51414-25-6 [3] Skin Sens. 1A H317 GHS07 Wng H317’       ‘607-716-00-8 bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2 H -chromen-2-one 249-205-9 28772-56-7 Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H330 H310 H300 H372 (blood) H400 H410 GHS08 GHS06 GHS09 Dgr H360D H330 H310 H300 H372 (blood) H410   Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood): 0,0005 % ≤ C < 0,005 % M = 1 M = 1’   ‘607-717-00-3 difethialone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2 H -1-benzothiopyran-2-one — 104653-34-1 Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H330 H310 H300 H372 (blood) H400 H410 GHS08 GHS06 GHS09 Dgr H360D H330 H310 H300 H372 (blood) H410 EUH070 Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 100 M = 100’   ‘607-718-00-9 perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts 206-801-3 [1] [2] [3] 375-95-1 [1] 21049-39-8 [2] 4149-60-4 [3] Carc. 2 Repr. 1B Lact. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam. 1 H351 H360Df H362 H332 H302 H372 (liver, thymus, spleen) H318 GSH08 GSH07 GHS05 Dgr H351 H360Df H362 H332 H302 H372 (liver, thymus, spleen) H318’       ‘607-719-00-4 dicyclohexyl phthalate 201-545-9 84-61-7 Repr. 1B Skin Sens. 1 H360D H317 GHS08 GHS07 Dgr H360D H317’       ‘608-067-00-3 3,7-dimethylocta-2,6-dienenitrile 225-918-0 5146-66-7 Muta. 1B H340 GHS08 Dgr H340’       ‘612-288-00-0 bupirimate (ISO); 5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate 255-391-2 41483-43-6 Carc. 2 Skin Sens. 1B Aquatic Chronic 1 H351 H317 H410 GHS08 GHS07 GHS09 Wng H351 H317 H410   M = 1’   ‘612-289-00-6 triflumizole (ISO); (1 E )- N -[4-chloro-2-(trifluoromethyl)phenyl]-1-(1 H -imidazol-1-yl)-2-propoxyethanimine — 68694-11-1 Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H302 H373 (liver) H317 H400 H410 GHS08 GHS07 GHS09 Dgr H360D H302 H373 (liver) H317 H410   M = 1 M = 1’   ‘616-218-00-X benzovindiflupyr (ISO); N -[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1 H -pyrazole-4-carboxamide — 1072957-71-1 Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H331 H301 H400 H410 GHS06 GHS09 Dgr H331 H301 H410   M = 100 M = 100’   ‘616-219-00-5 fluopyram (ISO); N -{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide — 658066-35-4 Aquatic Chronic 2 H411 GHS09 H411’       ‘616-220-00-0 pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea 266-096-3 66063-05-6 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 1 M = 1’   ‘617-023-00-2 tert -butyl hydroperoxide 200-915-7 75-91-2 Muta. 2 H341 GHS08 Wng H341’

Other acts of the same type
Commission Implementing Regulation (EU) 2015/2184 of 25 November 2015 amending Regulation (EC) No 1484/95 as regards fixing representative prices in the poultrymeat and egg sectors and for egg albuminRegulation (EU) 2015/2219 of the European Parliament and of the Council of 25 November 2015 on the European Union Agency for Law Enforcement Training (CEPOL) and replacing and repealing Council Decision 2005/681/JHARegulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001 (Text with EEA relevance)Regulation (EU) 2015/2284 of the European Parliament and of the Council of 25 November 2015 repealing Council Directive 76/621/EEC relating to the fixing of the maximum level of erucic acid in oils and fats and Council Regulation (EC) No 320/2006 establishing a temporary scheme for the restructuring of the sugar industryRegulation (EU) 2015/2365 of the European Parliament and of the Council of 25 November 2015 on transparency of securities financing transactions and of reuse and amending Regulation (EU) No 648/2012 (Text with EEA relevance)Commission Delegated Regulation (EU) 2016/79 of 25 November 2015 amending Annex III to Regulation (EU) No 978/2012 of the European Parliament and of the Council applying a scheme of generalised tariff preferencesCommission Delegated Regulation (EU) 2015/2170 of 24 November 2015 amending Directive 2014/24/EU of the European Parliament and of the Council in respect of the application thresholds for the procedures for the award of contracts (Text with EEA relevance)Commission Delegated Regulation (EU) 2015/2171 of 24 November 2015 amending Directive 2014/25/EU of the European Parliament and of the Council in respect of the application thresholds for the procedures for the award of contracts (Text with EEA relevance)Commission Delegated Regulation (EU) 2015/2172 of 24 November 2015 amending Directive 2014/23/EU of the European Parliament and of the Council in respect of the application thresholds for the procedures for the award of contracts (Text with EEA relevance)Commission Implementing Regulation (EU) 2015/2174 of 24 November 2015 on the indicative compendium of environmental goods and services, the format for data transmission for European environmental economic accounts and modalities, structure and periodicity of the quality reports pursuant to Regulation (EU) No 691/2011 of the European Parliament and of the Council on European environmental economic accounts (Text with EEA relevance)Commission Implementing Regulation (EU) 2015/2196 of 24 November 2015 approving non-minor amendments to the specification for a name entered in the register of protected designations of origin and protected geographical indications (Torta del Casar (PDO))Commission Implementing Regulation (EU) 2015/2266 of 24 November 2015 entering a name in the register of protected designations of origin and protected geographical indications [Asperges du Blayais (PGI)]

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next